The pharmaceutical intermediates market studied is anticipated to grow with a CAGR of nearly 5.3%, during the forecast period (2022 - 2027).
Pharmaceutical intermediates have been essential in reducing the COVID-19 pandemic and will continue to be fundamental in preventing both further waves of this pandemic and future outbreaks of infectious diseases. According to a study that was published in the American Chemical Society Pharmacology and Translational Science, 2020, new potential therapeutics for COVID-19 were discovered using a combined virtual and experimental screening strategy. Furthermore, they choose among the medications that were already in use and were examined to check for structural similarity against a library of almost 4,000 medications that were already in use, with hydroxychloroquine (HCQ) serving as a reference medication. The study suggested remdesivir and favipiravir therapies as prospective adjuvants in COVID-19 treatment and zuclopenthixol, nebivolol, and amodiaquine as potential candidates for clinical trials against the early phase of the SARS-CoV-2 infection. Thus, the pharmaceutical intermediates market is likely to increase both during and after a covid pandemic. As a result, market growth is anticipated in the coming years.
Specific factors that are driving the market growth include the increasing prevalence of chronic diseases and growing R&D initiatives and activities in the pharmaceutical industry. Given that these pharma intermediates are used in the treatment for cancer detection and a variety of chronic diseases, the rise in the prevalence of chronic diseases is projected to propel market expansion in the area under study. For instance, chronic diseases account for around 41 million annual fatalities, or 71% of all fatalities worldwide, according to the World Health Organization's key facts on non-communicable diseases published in April 2021. The high fatality rate from these diseases increases the demand for early intervention, which in turn propels the market's expansion.
The market is expected to develop due to the rising prevalence of respiratory ailments such as lung cancer, chronic obstructive pulmonary diseases, and others. For instance, the World Health Organization said that Chronic Obstructive Pulmonary Disease (COPD) is the third most common cause of mortality globally in its article titled "Chronic Obstructive Pulmonary Disease (COPD)" which was updated in January 2022. Nearly 3.23 million people have died as a result of it in 2019, and more than 80% of those deaths took place in low- and middle-income nations (LMIC). The necessity for effective treatment of the disease is brought on by the increasing prevalence of the chronic obstructive pulmonary disease. Thus, increasing disease prevalence is expected to increase market growth.
There has been an upsurge in the usage of advanced technologies, such as high throughput, bioinformatics, and combinatorial chemistry for better drug candidate identification. The discovery and development of novel drugs to treat, prevent, or cure a number of diseases, including cancer, diabetes, cardiovascular disorders, and chronic kidney disease, has been hampered by the significant rise in disease incidence rates around the world. The United States' health care spending climbed 9.7% to reach USD 4.1 trillion in 2020, a substantially greater rate than the 4.3% increase recorded in 2019, according to the PETERSON-KFF Health System Tracker data published in February 2022. The government health care budget was increased by 36.0% in 2020, partly as a result of the COVID-19 pandemic, which is what caused the acceleration. Additionally, increased investments in R&D are a significant driver of market expansion. For instance, JSR life sciences introduced a corporate venture fund in March 2021 with a focus on small and developing biotech, attracting clients to its range of life sciences services. The pharmaceutical business spent USD 83 billion on R&D in 2019, according to information released by the Congressional Budget Office in 2021. Hence, owing to the rising R&D activities in the pharmaceutical industry, the usage of pharmaceutical intermediates is expected to observe a steady growth as well.
However, stringent regulatory issues regarding certain pharmaceutical intermediate substances are expected to hinder the market growth.
As per the scope of the report, pharmaceutical intermediates are the drugs used as raw materials for the production of bulk drugs, or they can refer to a material produced during the synthesis of an API that must undergo further molecular change or processing before it becomes an API. Drug intermediates are hygienically formulated using high-grade raw materials and they are used in the pharmaceutical and a few other industries such as the cosmetic industry etc. The Pharmaceutical Intermediates Market is Segmented by Type (Chemical Intermediate, Bulk Drug Intermediate, and Others), Application (Analgesics, Anti-Infective Drugs, Cardiovascular Drugs, Oral Antidiabetic Drugs, Antimicrobial Drugs, and Others), End-User (Biotech and Pharma Companies, Research Institutions, and Others), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
By Type Chemical Intermediate Bulk Drug Intermediate Others By Application Analgesics Anti-Infective Drugs Cardiovascular Drugs Oral Antidiabetic Drugs Antimicrobial Drugs Others By End-User Biotech and Pharma Companies Research Institutions Others Geography North America United States Canada Mexico Europe Germany United Kingdom France Italy Spain Rest of Europe Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific Middle-East and Africa GCC South Africa Rest of Middle-East and Africa South America Brazil Argentina Rest of South AmericaThe burden of heart disease on the nation's healthcare system is on the rise. One of the main elements driving the market expansion of pharmaceutical intermediates is the increase in the incidence of chronic cardiovascular disorders such as heart failure and coronary artery diseases. Ischemic heart disease (IHD) is a primary cause of death worldwide, according to a report published in the Cureus Journal of Medical Science in July 2020. Around 126 million people worldwide (1,655 per 100,000), or roughly 1.72% of the world's population are affected by ischemic heart disease. By 2030, it is anticipated that there would be more than 1,845 cases of ischemic heart disease per 100,000 people worldwide.
According to the Australian Bureau of Statistics report on the major causes of death in Australia in 2019, ischaemic heart disease accounted for 10.8% of all fatalities there. Similarly, the "UK Factsheet" by the British Heart Foundation, released in July 2021, estimated that 7.6 million people in the United Kingdom were affected by heart and circulation disorders. Additionally, according to the same source, heart and circulation illnesses are responsible for more than 1,60,000 deaths annually in the United Kingdom, or 25% of all fatalities in the country. This high prevalence of cardiovascular diseases is generating a huge demand for cardiovascular drugs, which, in turn, is expected to propel the growth in the need for various pharmaceutical intermediates.
Hence, owing to the aforementioned factors, the concerned segment of the pharmaceutical intermediates market is expected to observe steady growth over the forecast period.
North America dominates the Pharmaceutical Intermediates products market primarily due to the advanced research and development facilities mainly across the United States and Canada. In addition, the rising prevalence of various chronic conditions is also fueling market growth across the region. Growing government support for healthcare in the United States is one element contributing to the market's expansion in that country. For instance, the National Institutes of Health (NIH) received more than USD 700 billion in public funding over the past few decades, according to a 2021 study from the Congressional Budget Office. Six grants were given out by the Food and Drug Administration (FDA) in 2020 to fund new clinical trials and advance the creation of pharmaceuticals for the treatment of uncommon diseases. The need for pharmaceutical intermediates, which are widely used in the drug discovery process, will increase as a result. According to "clinicaltrials.gov," there were 140,974 registered clinical studies in the United States as of April 2021. Similarly, according to ClinicalTrial.gov, Canadian pharmaceutical companies and research institutions have strong R&D pipelines as of April 2021. Of the 5,659 new studies in the pipeline at that time that were in various stages of evaluation, 1,397 (24%) were in Phase III clinical trials that had received the Food and Drug Administration (FDA) or European Medicines Evaluation Agency (EMA) approval, covering a wide range of therapeutic areas.
As infectious diseases become more widespread, attention is being paid more and more to their diagnosis and treatment. The Center for Disease Control and Prevention (CDC) estimated that in 2020, there were approximately 7,174 tuberculosis cases discovered in the United States, translating to a rate of 2.2 per 100,000 people. Thus, a high prevalence of tuberculosis patients drives up the demand for therapy, which in turn drives the market for pharmaceutical intermediates. The CDC reported in a February 2022 article that each year in the United States, Salmonella bacteria causes around 1.35 million infections, 26,500 hospitalizations, and 420 fatalities. The nation's healthcare system is burdened by the large number of infectious infections that are reported each year. As a result, the market under study may experience growth due to the extraordinary rise in demand for treatments for these diseases. Thus, the abovementioned factors are expected to increase the market growth.
The global pharmaceutical intermediates market is competitive and consists of a few major players. Companies like Aceto Corporation, BASF SE, Chiracon GmbH, Yin-sheng Bio-tech Co., Ltd., Dishman Group, Green Vision Life Sciences, Codexis, Inc., Sanofi SAIS, Vertellus Holdings LLC., among others, hold the substantial market share in the market.
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Chronic Diseases
4.2.2 Growing R&D Initiatives and Activities in the Pharmaceutical Industry
4.3 Market Restraints
4.3.1 Sringent Regulatory Issues Regarding Certain Pharmaceutical Intermediate Substances
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Type
5.1.1 Chemical Intermediate
5.1.2 Bulk Drug Intermediate
5.1.3 Others
5.2 By Application
5.2.1 Analgesics
5.2.2 Anti-Infective Drugs
5.2.3 Cardiovascular Drugs
5.2.4 Oral Antidiabetic Drugs
5.2.5 Antimicrobial Drugs
5.2.6 Others
5.3 By End-User
5.3.1 Biotech and Pharma Companies
5.3.2 Research Institutions
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 A.R. Life Science
6.1.2 Aceto Corporation
6.1.3 BASF SE
6.1.4 Chiracon GmbH
6.1.5 Codexis, Inc.
6.1.6 Dishman Group
6.1.7 Green Vision Life Sciences
6.1.8 Lianhetech
6.1.9 Midas Pharma GmbH
6.1.10 Sanofi SAIS
6.1.11 Vertellus Holdings LLC
6.1.12 Yin-sheng Bio-tech Co., Ltd.
*List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
The Global Pharmaceutical Intermediates Market market is studied from 2019 - 2027.
The Global Pharmaceutical Intermediates Market is growing at a CAGR of 5.3% over the next 5 years.
Asia Pacific is growing at the highest CAGR over 2021- 2026.
North America holds highest share in 2021.
Chiracon GmbH , BASF SE, Sanofi SAIS, Aceto, Codexis, Inc. are the major companies operating in Global Pharmaceutical Intermediates Market.
80%
of our clients seek made-to-order reports. How do you want us to tailor yours?Please enter a valid email id!
Please enter a valid message!